# SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

> **NCT05896046** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed or Refractory Hodgkin Lymphoma

## Interventions

- **DRUG:** SHR2554+ SHR1701
- **DRUG:** SHR-1701

## Key facts

- **NCT ID:** NCT05896046
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896046, "SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05896046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*